BiotechTube

Ixekizumab + Adalimumab

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Psoriatic Arthritis

Conditions

Psoriatic Arthritis

Trial Timeline

Aug 24, 2017 → Sep 4, 2019

NCT ID
NCT03151551

About Ixekizumab + Adalimumab

Ixekizumab + Adalimumab is a approved stage product being developed by Eli Lilly for Psoriatic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03151551. Target conditions include Psoriatic Arthritis.

What happened to similar drugs?

9 of 20 similar drugs in Psoriatic Arthritis were approved

Approved (9) Terminated (0) Active (11)
✅TirzepatideEli LillyApproved
✅GuselkumabJohnson & JohnsonApproved
✅methotrexate (MTX) + adalimumab (ADA)AbbVieApproved
✅Upadacitinib 15 MG [Rinvoq] + PlaceboAbbVieApproved
✅Secukinumab 300 mg + Secukinumab 150 mgNovartisApproved
✅ApremilastAmgenApproved
✅Apremilast (CC-10004)AmgenApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04527380Phase 3Active
NCT03151551ApprovedCompleted

Competing Products

20 competing products in Psoriatic Arthritis

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
Sonelokimab + Placebo + AdalimumabMoonLake ImmunotherapeuticsPhase 2
29
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
41
Dose A VTX958 + Dose B VTX958 + PlaceboVentyx BiosciencesPhase 2
21
Ixekizumab + PlaceboEli LillyPhase 3
40
Ixekizumab + TirzepatideEli LillyPre-clinical
33
Ixekizumab + TirzepatideEli LillyPhase 3
44
Alefacept + Methotrexate + PlaceboAstellas PharmaPhase 2
35
SUNPG18_07 I (Tildrakizumab 200 mg) + SUNPG18_07 II (Tildrakizumab 100 mg)Sun PharmaceuticalPhase 2/3
38
TILD sub-cutaneous (SC) injectionSun PharmaceuticalPhase 3
44
SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBOSun PharmaceuticalPhase 2
35
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
40
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
44
Ixekizumab + AdalimumabEli LillyPhase 3
44
TirzepatideEli LillyApproved
50
Placebo + Ixekizumab 80 mg Q4W + Ixekizumab 80 mg Q2WEli LillyPhase 3
40
GuselkumabJohnson & JohnsonApproved
50
RSS0393 ointment + RSS0393 ointment + RSS0393 ointment placeboJiangsu Hengrui MedicinePhase 2
42
SHR0302 tablets、Placebo + SHR0302 tablets、Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
36